It’s not just the paranoia of Fed-bashing, hard money zealots: precious metals really do make a lot of sense now. Fact is, the market’s wild intraday gyrations are giving investors the cold sweats. With some analysts calling for a market crash in 2019, gold and silver are starting to regain… Read More
John Persinos is the editorial director of Investing Daily, overseeing such publications as Personal Finance, Utility Forecaster, Profit Catalyst Alert, Rapier's Income Accelerator, Income Forecaster, and Marijuana Investing Daily, among others. John also writes the Mind Over Markets daily stock market recap, and he's the chief investment strategist of Marijuana Profit Alert.
John has decades of experience in the technology and political realms. He has worked as a staff editor at Inc. and Venture magazines, and written for Kiplinger's, Street Authority, Investing Answers, and TheStreet.com, to name a few. In a career that has spanned more than 40 years, John has been diligently and prolifically covering the news and its impact on investors.
John also has experience with the inner-workings of Capitol Hill, serving as a press secretary to U.S. Rep. Byron Dorgan (D-ND). John started his career as a daily newspaperman with The Orlando Sentinel.
John holds undergraduate and graduate degrees from Boston University. He also completed the Davenport Fellowship in Business and Economics Reporting at the University of Missouri (Columbia).
Analyst Articles
It’s during fraught times like these, with market volatility and worsening headline risk, that technology “disruptors” prove their mettle. That’s because they defy the status-quo and introduce disruptive new technologies that create entirely new industries and products. The stocks of quality disruptors tend to rise over the long haul, regardless… Read More
You probably remember the iconic 1970s television show The Six Million Dollar Man, about a wounded astronaut who is given superhuman strength through bionic implants. The popular series led to a spin-off, The Bionic Woman. Today, several companies in the field of human bionics are turning science fiction into science… Read More
The race is on for new sources of growth in the biopharmaceutical industry, as blockbuster drugs lose patent protection and competitors join forces to cut costs. It spells outsized growth for the right biotech company, especially one that’s about to benefit from imminent events and technical factors that could send… Read More
In the annals of consumer technology fads, a special place belongs to Fitbit (NYSE: FIT), maker of wearable fitness-tracking devices. The San Francisco-based company’s wristbands and clippable devices monitor fitness activity, such as calories burned or distance covered. Yep, the company’s gadgets have been all the rage. However, does the… Read More
Unless you live in a cave or you’re from another planet, you already know about Facebook as a social network. But what about the company as a stock? As an investor, should you buy — or unfriend — the stock? Let’s find out. Read More
One plus one equals three. That’s the math Wall Street often applies to mergers or spin-offs. Does this magical arithmetic apply to HP (NYSE: HPQ)? The giant personal computer (PC) maker is the product of a complex spin-off that continues to entice — but also confound — investors. Let’s find… Read More
One stock that garners a lot of splashy news headlines, both positive and negative, is Broadcom (NSDQ: AVGO). What’s relevant and what’s hyperbole? Below, we sift through the Broadcom drama to determine the key takeaways for investors. Read More
What makes a company that isn’t publicly traded worth talking about? It’s because Publix is a widely respected, much-discussed company that could very well go public in 2019. Rumors continually swirl on Wall Street that Publix might soon launch an initial public offering (IPO). Read More
Groupon continually disappoints expectations, but the stock’s adherents refuse to throw in the towel. So which is it? Is Groupon a value play or a value trap? Read More